Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is expressed by in vitro activated natural killer (NK) cells, but the relevance of this observation to the biological function of NK cells has been unclear. Herein, we have demonstrated the in vivo induction of mouse TRAIL expression on various tissue NK cells and correlated NK cell activation with TRAIL-mediated antimetastatic function in vivo. Expression of TRAIL was only constitutive on a subset of liver NK cells, and innate NK cell control of Renca carcinoma hepatic metastases in the liver was partially TRAIL dependent. Administration of therapeutic doses of interleukin (IL)-12, a powerful inducer of interferon (IFN)-γ production by NK cells and NKT cells, upregulated TRAIL expression on liver, spleen, and lung NK cells, and IL-12 suppressed metastases in both liver and lung in a TRAIL-dependent fashion. By contrast, α-galactosylceramide (α-GalCer), a powerful inducer of NKT cell IFN-γ and IL-4 secretion, suppressed both liver and lung metastases but only stimulated NK cell TRAIL-mediated function in the liver. TRAIL expression was not detected on NK cells from IFN-γ–deficient mice and TRAIL-mediated antimetastatic effects of IL-12 and α-GalCer were strictly IFN-γ dependent. These results indicated that TRAIL induction on NK cells plays a critical role in IFN-γ–mediated antimetastatic effects of IL-12 and α-GalCer.
Skip Nav Destination
Article navigation
19 March 2001
Article|
March 12 2001
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis
Mark J. Smyth,
Mark J. Smyth
aCancer Immunology, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria 3002, Australia
Search for other works by this author on:
Erika Cretney,
Erika Cretney
aCancer Immunology, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria 3002, Australia
Search for other works by this author on:
Kazuyoshi Takeda,
Kazuyoshi Takeda
dDepartment of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Search for other works by this author on:
Robert H. Wiltrout,
Robert H. Wiltrout
bLaboratory of Experimental Immunology, Division of Basic Sciences, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702
Search for other works by this author on:
Lisa M. Sedger,
Lisa M. Sedger
cDepartment of Pathology, The University of Sydney, Sydney, New South Wales 2006, Australia
Search for other works by this author on:
Nobuhiko Kayagaki,
Nobuhiko Kayagaki
dDepartment of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Search for other works by this author on:
Hideo Yagita,
Hideo Yagita
dDepartment of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Search for other works by this author on:
Ko Okumura
Ko Okumura
dDepartment of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Search for other works by this author on:
Mark J. Smyth
aCancer Immunology, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria 3002, Australia
Erika Cretney
aCancer Immunology, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria 3002, Australia
Kazuyoshi Takeda
dDepartment of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Robert H. Wiltrout
bLaboratory of Experimental Immunology, Division of Basic Sciences, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702
Lisa M. Sedger
cDepartment of Pathology, The University of Sydney, Sydney, New South Wales 2006, Australia
Nobuhiko Kayagaki
dDepartment of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Hideo Yagita
dDepartment of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Ko Okumura
dDepartment of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan
Abbreviations used in this paper: α-GalCer, α-galactosylceramide; asGM1, asialo GM1; CMA, concanamycin A; MNC, mononuclear cell; pfp, perforin; TRAIL, TNF-related apoptosis-inducing ligand; WT, wild-type.
Received:
October 13 2000
Revision Requested:
January 22 2001
Accepted:
January 31 2001
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2001 The Rockefeller University Press
2001
The Rockefeller University Press
J Exp Med (2001) 193 (6): 661–670.
Article history
Received:
October 13 2000
Revision Requested:
January 22 2001
Accepted:
January 31 2001
Citation
Mark J. Smyth, Erika Cretney, Kazuyoshi Takeda, Robert H. Wiltrout, Lisa M. Sedger, Nobuhiko Kayagaki, Hideo Yagita, Ko Okumura; Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis. J Exp Med 19 March 2001; 193 (6): 661–670. doi: https://doi.org/10.1084/jem.193.6.661
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement